Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

HJHafiz Muhammad Asif JavedFSFatima SialHSHafsa Shahid

Discussion

Loading...

Member takes

Overview

Systematic review finds high complete response and progression-free survival in chronic lymphocytic leukemia patients using BTK inhibitors and venetoclax, suggesting effective treatment options.

Key Points

  • Pooled complete response rate of 51% indicates significant efficacy of BTK inhibitor and venetoclax combination.
  • The meta-analysis evaluated 1,163 patients across 10 studies to determine treatment outcomes for chronic lymphocytic leukemia.
  • Overall survival was reported at 94%, highlighting the potential benefits of this treatment regimen.
  • Further high-quality trials are needed to confirm these promising results and refine treatment protocols.

Cite This Study

Javed et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d505https://doi.org/10.1182/blood-2025-7432
View Full Paper
Ask AI
Bookmark
Share